Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 3, 2012, Pages

  Winter Roach, Brett A ^a   Kitchener, Henry C ^b   Lawrie, Theresa A ^c  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; MELPHALAN;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; FEMALE; HUMAN; META ANALYSIS; METHODOLOGY; OVARY TUMOR; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MELPHALAN; NEOPLASM STAGING; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861954968     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004706.pub4     Document Type: Review

References (62)

1. Timmers PJZ. Understanding the problem of inadequately staging early ovarian cancer. European Journal of Cancer 2010;46(5):880-4.
2. Trimbos B, Timmers P, Pecorelli S, Coens C, Ven K, van der Burg M, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. Journal of the National Cancer Institute 2010;102(13):982-7.
3. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III. trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. Journal of the National Cancer Institute 2003;95(2):105-12.
4. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma. Journal of the National Cancer Institute 2003;95(2):113-25.
5. Vergote IB, Trimbos BJ, Guthrie D, Parmar M, Bolis G, Mangioni C, et al. Results of a randomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery [abstract]. Proceedings of the American Society of Clinical Oncology. 2001; Vol. 20 (Part 1):201a.
6. Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni S, Bonazzi C, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Annals of Oncology 1995;6(9):887-93.
7. Erratum: "International collaborative ovarian neoplasm trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer" (Journal of the National Cancer Institute (2003) vol. 95 (2) (125-32)). Journal of the National Cancer Institute 2003;95(10):764.
8. Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. Journal of the National Cancer Institute 2003;95(2):125-32.
9. Colombo N, Pecorelli S. What have we learned from ICON1 and ACTION?. International Journal of Gynecological Cancer 2003;13(Suppl 2):140-3.
10. Colombo N, Trimbos JB, Guthrie D, Vergote I, Mangioni C, Vermorken J, et al. ACTION + ICON1: two parallel randomised phase III. trials comparing adjuvant chemotherapy to no adjuvant chemotherapy following surgery in women with high risk early ovarian cancer [abstract]. European Journal of Cancer 2001;37(Suppl 6):276.
11. Swart AC on behalf of ICON collaborators. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy for early stage ovarian cancer (ICON1). Journal of Clinical Oncology 2007;25(18S):5509.
12. Trope C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Annals of Oncology 2000;11(3):281-8.
13. Trope C, Kaern J, Vergote I, Hagen B, Rosenberg P, Bertelsen K, et al. Randomized trial on adjuvant carboplatin versus no treatment in Stage I high risk ovarian cancer by the Nordic Ovarian Cancer Study Group (NOCOVA) [abstract]. Proceedings of the American Society of Clinical Oncology. 1997; Vol. 16:352a.
14. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al. Adjuvant therapy in stage I and stage II. epithelial ovarian cancer. Results of two prospective randomized trials. New England Journal of Medicine 1990;322(15):1021-7.
15. Chiara S, Conte P, Franzone P, Orsatti M, Bruzzone M, Rubagotti A, et al. High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy. American Journal of Clinical Oncology 1994;17(1):72-6.
16. Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF, Sturgeon J, et al. Ovarian carcinoma: improved survival following abdominopelvic irradiation in patients with a completed pelvic operation. American Journal of Obstetrics and Gynecology 1979;134(7):793-800.
17. Gronroos M, Nieminen U, Kauppila A. A prospective, randomized, national trial for treatment of ovarian cancer: the role of chemotherapy and external irradiation. European Journal of Obstetrics, Gynaecology and Reproductive Biology 1984;17(1):33-42.
18. Hreshchyshyn MM, Park RC, Blessing JA, Norris HJ, Levy D, et al. The role of adjuvant therapy in stage I ovarian cancer. American Journal of Obstetrics and Gynecology 1980;138(2):139-45.
19. Dent SF, Klaassen D, Pater JL, Zee B, Whitehead M. Second primary malignancies following the treatment of early stage ovarian cancer: update of a study by the National Cancer Institute of Canada--Clinical Trials Group (NCIC-CTG). Annals of Oncology 2000;11(1):65-8.
20. Klaassen D, Shelley W, Starreveld A, Kirk M, Boyes D, Gerulath A, et al. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report. Journal of Clinical Oncology 1988;6(8):1254-63.
21. Kojs Z, Glinski B, Reinfuss M, Pudelek J, Urbanski K, Kowalska T, et al. Results of a randomized prospective trial comparing postoperative abdominopelvic radiotherapy with postoperative chemotherapy in early ovarian cancer. Cancer Radiotherapie 2001;5(1):5-11.
22. Maggioni A, Benedetti Panici P, Dell'Anna T, Landoni F, Lissoni A, Pellegrino A, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. British Journal of Cancer 2006;95(6):699-704.
23. Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, et al. A randomized phase III. trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecological Oncology 2011;122(1):89-94.
24. Sell A, Bertelsen K, Andersen JE, Stroyer I, Panduro J, Bentzen SM, et al. Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecologic Oncology 1990;37(3):367-73.
25. Sevelda P, Gitsch E, Dittrich C, Haider F, Czerwenka K, Schemper M, et al. Therapeutic and prognostic results of a prospective multicenter ovarian cancer study of FIGO stages I and II. Geburtshilfe Frauenheilkd 1987;47(3):179-85.
26. Sigurdsson K, Johnsson JE, Trope C. Carcinoma of the ovary, stages I and II. A prospective randomized study of the effects of postoperative chemotherapy and radiotherapy. Annales Chirurgiae et Gynaecologiae 1982;71(6):321-9.
27. Smith JP, Rutledge FN, Delclos L, Mayer AR, Chambers SK, Graves E, et al. Results of chemotherapy as an adjunct to surgery in patients with localized ovarian cancer. Seminars in Oncology 1975;2(3):277-81.
28. Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard MW, Kjorstad KE, et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992;69(3):741-9.
29. Bell J, Brady MF, Young RC, Walker JL, Look KY, Rose GS, et al. Randomised phase III. trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology 2006;102(3):432-9.
30. Young RC. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer. Seminars in Oncology 2000;27(3 Suppl 7):8-10.
31. Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, et al. Adjuvant treatment for early ovarian cancer: a randomized phase III. trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study. Journal of Clinical Oncology 2003;21(23):4350-5.
32. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. British Journal of Cancer 1995;72:511-8.
33. Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer. Cochrane Database of Systematic Reviews 1999, Issue 1. [DOI: 10.1002/14651858.CD001418]
34. Bell J, Brady MF, Young RC, Walker JL, Look KY, Rose GS, et al. Randomised phase III. trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology 2006;102(3):432-9.
35. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. Journal of Clinical Oncology 1989;13(8):2147-8.
36. Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. Journal of the National Cancer Institute 2003;95(2):125-32.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
38. Elit L, Chambers A, Fyles A, Covens A, Carey M, Fung MF. Systematic review of adjuvant care for women with stage I ovarian carcinoma. Cancer 2004;101(9):1926-35.
39. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer [Internet] 2010; Vol. Lyon, France:Available from: http://globocan.iarc.fr.
40. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III. and stage IV ovarian cancer. New England Journal of Medicine 1996;334(1):1-6.
41. Green JA. Early ovarian cancer--time for a rethink on stage. Gynecologic Oncology 2003;90:235-7.
42. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.1 [updated March 2011]. The Cochrane Collaboration 2011 Available from www.cochrane-handbook.org.
43. ICON collaborators. ICON2: randomised trial of single agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON. International Collaborative Neoplasm Study. Lancet 1998;352:1571-6.
44. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer Statistics, 2008. CA: A Cancer Journal for Clinicians 2008;58:71-96.
45. Mayer AR, Chambers SK, Graves E, Holm C, Tseng PC, Nelson BE, et al. Ovarian cancer staging: does it require a gynecologic oncologist?. Gynecologic Oncology 1992;47:223-7.
46. Morice P, Wicart-Poque F, Rey A, El-Hassan J, Pautier P, Lhommé C, et al. Results of conservative treatment in epithelial ovarian carcinoma. Cancer 2001;92:2412-8.
47. National Collaborating Centre for Cancer. Ovarian cancer: NICE clinical guideline 122. http://www.nice.org.uk/nicemedia/live/13464/54268/54268.pdf April 2011.
48. National Cancer Institute. National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0). http://www.eortc.be/services/doc/ctc/ctcaev3.pdf 2006.
49. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
50. Peto R. Statistical aspects of cancer trials. In: Halnan KE editor(s). Treatment of Cancer. London: Chapman and Hall, 1982.
51. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
52. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94-results and commentary. Annals of Oncology 2003;14:v61-v118. [: Supplement 5]
53. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecologic Oncology 2002;87(1):1-7.
54. Shepherd JH. Revised FIGO staging for gynaecological cancer. British Journal of Obstetrics and Gynaecology 1989;96:889-92.
55. Swart AC on behalf of ICON collaborators. Long-term follow-up of women enrolled in a randomized trial of adjuvant chemotherapy in early stage ovarian cancer (ICON1). Journal of Clinical Oncology. Chicago: ASCO Annual Meeting Proceedings, 2007; Vol. 25.
56. Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W and the Gynecologic Cancer InterGroup. First line therapy in ovarian cancer trials. International Journal of Gynecological Cancer 2011;21(4):756-62.
57. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma. Journal of the National Cancer Institute 2003;95(2):113-25.
58. Trimbos B, Timmers P, Pecorelli S, Coens C, Ven K, van der Burg M, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. Journal of the National Cancer Institute 2010;102(13):982-7.
59. Trope C, Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. Journal of Clinical Oncology 2007;25(20):2909-20.
60. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Selvelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage 1 invasive epithelial carcinoma. Lancet 2001;357:176-82.
61. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Torri V, et al. The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. Annals of Oncology 1998;9(10):1097-101.
62. Winter-Roach B, Hooper L, Kitchener H. Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. International Journal of Gynecological Cancer 2003;13(4):395-404.